ALPN - Alpine Immune Sciences - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

3.918B

Cash

327.4M

Avg Qtr Burn

-19.75M

Short % of Float

10.55%

Insider Ownership

4.65%

Institutional Own.

91.10%

Qtr Updated

12/31/23

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Povetacicept (ALPN-303) Details Autoimmune disease, Immune complex membranoproliferative glomerulonephritis, Autoimmune nephritis, IgA nephropathy	Phase 3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Acazicolcept (ALPN-101) Details Systemic lupus erythematosus	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Povetacicept (ALPN-303) Details Autoimmune disease, Systemic lupus erythematosus	Phase 2 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Povetacicept (ALPN-303) Details Autoimmune disease, Primary immune thrombocytopenia	Phase 1b Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Davoceticept (ALPN-202) (CD28 costimulator) Details Advanced malignancies	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.